190 related articles for article (PubMed ID: 24511052)
21. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M; Yohe S; Weisdorf D; Ustun C
Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome.
Manola KN; Panitsas F; Polychronopoulou S; Daraki A; Karakosta M; Stavropoulou C; Avgerinou G; Hatzipantelis E; Pantelias G; Sambani C; Pagoni M
Cancer Genet; 2013 Mar; 206(3):63-72. PubMed ID: 23411131
[TBL] [Abstract][Full Text] [Related]
23. [An analysis of cytogenetic characteristics and prognosis of 189 t (8; 21) acute myeloid leukemia patients].
Liu XP; Xue YP; Liu SH; Mi YC; Han MZ; Xiao ZJ; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):918-21. PubMed ID: 17313880
[TBL] [Abstract][Full Text] [Related]
24. Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
Corral Mdel P; Villa O; Alfaro EM; Alonso CN; Baro C; Felice MS; Rossi J; Solé F; Gallego MS
Pediatr Blood Cancer; 2008 Mar; 50(3):651-4. PubMed ID: 17405156
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
[TBL] [Abstract][Full Text] [Related]
26. [Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse].
Wakazono Y; Kataoka A; Fusaoka T; Tunamoto K
Rinsho Ketsueki; 1998 Jul; 39(7):499-505. PubMed ID: 9750457
[TBL] [Abstract][Full Text] [Related]
27. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
28. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
29. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
30. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
31. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; von Neuhoff C; Sander A; Schrauder A; Teigler-Schlegel A; Stary J; Corbacioglu S; Reinhardt D
Blood; 2011 Nov; 118(20):5409-15. PubMed ID: 21948298
[TBL] [Abstract][Full Text] [Related]
32. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
33. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
[TBL] [Abstract][Full Text] [Related]
35. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Marcucci G; Caligiuri MA; Bloomfield CD
Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
[TBL] [Abstract][Full Text] [Related]
36. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Schlenk RF; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
J Clin Oncol; 2004 Sep; 22(18):3741-50. PubMed ID: 15289486
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
38. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
39. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
40. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
